Phthisis Diagnostics Announces Second Round of Funding
With their first product already in the international marketplace and a second just launched, Phthisis Diagnostics has announced a successful second round of angel funding raising $410,000.
“We are delighted to have this additional investor support. This will enable us to continue marketing our existing products and to continue expansion of our product lines,” observed Crystal Icenhour, PhD, President and Chief Science Officer for Phthisis. “The funding will be used to complete development and clinical trials for our first diagnostic for parasites. We expect to release this molecular diagnostic product within the next 18 months. Additional diagnostics for fungi and mycobacterium, as well as molecular standards for improved laboratory quality control, are also in development.”
“We are excited about the rapid progress the Phthisis team has made and their clear path to success,” said Bill Militello, Managing Principal at Piedmont Investment Advisors, a Leesburg, VA-based investment firm.
Recently, Dr. Icenhour was featured as one of “40 Medtech Innovators Under 40” by industry publication MD+DI Medical Device and Diagnostic Industry News Products and Suppliers. Earlier this spring she was recognized with a prestigious national award for her success as an entrepreneur, combining science and business, when she was named the 2012 Ewing Marion Kauffman Foundation Outstanding Postdoctoral Entrepreneur by the Foundation and the National Postdoctoral Association (NPA).
The original investors, Piedmont Angel Network and New Dominion Angels, have contributed $147,500 to this round and seven more investors have committed an additional $262,500 for a total of $410,000 in fresh funding. New investors in Phthisis Diagnostics include Piedmont Investment Advisors LLC (through its affiliate Militello Capital), MooDoos Limited Partnership, Ronald Harris, Virga Ventures LLC, Daniel Brody, and Afton Scientific NA LLC.